Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer

Population Pharmacokinetics and Exposure–Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer

PurposePaclitaxel liposome (Lipusu) is the first commercialized liposomal formulation of paclitaxel. There has been little data collected on the pharmacokinetics (PK) of paclitaxel liposome, especially in relation to patient use. This study aimed to build a population pharmacokinetic (PopPK) model a...

Full description

Bibliographic Details
Main Authors: Haiyan Zhou, Jiaqing Yan, Wei Chen, Jun Yang, Min Liu, Yuan Zhang, Xin Shen, Yinglin Ma, Xingsheng Hu, Yan Wang, Kehe Du, Guohui Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
paclitaxel liposome
population pharmacokinetics
exposure–safety relationship
model
non-small cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.01731/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.01731/full

Similar Items